More recently, Hourigan et al. used ultra-deep error-corrected sequencing for 13 commonly mutated myeloid genes (ASXL1, DNMT3A, FLT3, IDH1, IDH2, JAK2, KIT, NPM1, NRAS, RUNX1, SF3B1, TET2, and TP53) on pretransplant blood in patients with AML treated on a phase 3 clinical trial that randomly assigned patients with AML/MDS in morphologic remission to MAC or RIC. This evidence concerns the gene NPM1 and acute myeloid leukemia.